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Introduction:  Porous silicon (pSi) engineered by electrochemical etching has been used as a 
drug delivery vehicle to address the intrinsic limitations of traditional therapeutics. 
Biodegradability, biocompatibility and optoelectronic properties make pSi a unique candidate 
for developing biomaterials for theranostics and photodynamic therapies. This review 
presents an updated overview about the recent therapeutic systems based on pSi, with a 
critical analysis on the problems and opportunities that this technology faces as well as 
highlighting pSi’s growing potential.  
   
Areas Covered: Recent progress in pSi-based research includes drug delivery systems, 
including biocompatibility studies, drug delivery, theranostics and clinical trials with the 
most relevant examples of pSi-based systems presented here. A critical analysis about the 
technical advantages and disadvantages of these systems is provided along with an 
assessment on the challenges that this technology faces, including clinical trials and 
investors’ support.    
 
Expert Opinion: pSi is an outstanding material that could improve existing drug delivery and 
photodynamic therapies in different areas, paving the way for developing advanced 
theranostic nanomedicines and incorporating payloads of therapeutics with imaging 
capabilities. However, more extensive in-vivo studies are needed to assess the feasibility and 
reliability of this technology for clinical practice. The technical and commercial challenges 
that this technology face are still uncertain.   
 











From the beginning of the 20th century when Paul Ehrlich postulated his visionary 
concept of a “magic bullet” right up until the modern concept of nanomedicine, intensive 
activity in fundamental research and medical translation has been carried out for the 
development of nanomedicines. Omni-capable therapeutic systems have the potential to 
diagnose disease, deliver drugs and repair diseased organs [1-3]. The term, nanomedicine, 
refers to drug delivery systems that employ nanometer-scale materials in the form of 
nanoparticles (of various shapes and geometries) as carriers to encapsulate the therapeutic 
agents to be delivered at a target site with controlled release rate [4, 5]. The ultimate aim of 
drug delivery systems based on nanocarriers is to selectively target disease-causing 
organisms while keeping the rest of the host organism spared to minimize side effects and 
toxicity associated with non-targeted therapeutic substances. Furthermore, these systems can 
also overcome other intrinsic limitations of conventional medicines by enhancing their 
biodistribution, solubility, selectivity and pharmacokinetics [6, 7]. However, the modern 
concept of nanomedicine goes beyond simple drug delivery and more sophisticated forms of 
nanomedicines have been envisaged. For instance, theranostic agents combine both 
therapeutic and diagnostic entities into a single drug delivery carrier. This revolutionary 
concept has opened a plethora of possibilities, not only to treat diseases but also to diagnose 
and understand the biological response and progression of living systems to different 
treatments [8, 9]. Drug nanocarriers with theranostic capabilities enable imaging of 
nanomedicines to localize and monitor drug release and assess the therapeutic efficacy by 
analyzing the response to a given treatment in-situ, using numerous imaging modalities. 
Many different types of theranostic nanomedicines have been developed [10, 11]. Typically, 
these nanomedicines are composed of nanocarriers such as polymers, liposomes, micelles, 
antibodies and nanoparticles. In many cases, these vehicles are endowed with therapeutic and 
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diagnosis capabilities by co-loading drugs and imaging agents. However, some of these 
vehicles can offer intrinsic theranostic capabilities based on the chemical and physical 
properties of the nanocarrier, without additional co-loaded agents. Among these, porous 
silicon (pSi) is considered an outstanding platform to develop advanced drug delivery 
systems due to its unique set of physical and chemical properties, which can be precisely 
tuned by engineering its geometric features, surface chemistry and porosity.  
pSi produced by electrochemical etching of silicon was discovered by the Uhlirs in 
1956 at the Bell Laboratories [12-15]. Years after, Gösele and Canham identified quantum 
confinement effects in pSi structures, opening new opportunities to expand the application of 
pSi in optoelectronics [16, 17]. The unique optoelectronic properties of silicon and its porous 
forms make this the material of choice for microelectronic systems, the discovery of its 
biocompatibility and biodegradability by Canham in 1995 spread its use to drug delivery 
applications [18,19]. Canham demonstrated for the first time the in-vitro biocompatibility of 
pSi films featuring micro-, meso- and macro-porosity. His pioneering studies revealed that 
the biodegradability and biointegration of pSi structures could be modulated by the degree of 
porosity and the size of its pores. Canham’s works stimulated an increasing activity in the 
field of pSi for drug delivery applications and enabled new opportunities to use this material 
in medicine and related fields [20-22]. More recently, Sailor demonstrated for the first time 
that pSi-based nanoparticles (pSiNPs) can also act as imaging agents using a time-gated 
imaging approach by taking advantage of the pSi optoelectronic properties [23-25]. As a 
result, pSi is considered a unique and promising vehicle platform for theranostic 
nanomedicines.  
Although some companies such as pSiMedica Ltd UK have initiated the commercial 
development of nanomedicines based on pSi for clinical therapies, it is worthwhile noting 
that the bench-to-bedside translation of pSi-based drug delivery systems into clinical 
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nanomedicines faces both technical and commercial challenges [20]. For instance, 
nanotechnology is increasingly reaching the investors’ attention and drug delivery is expected 
to grow strongly in the next decade [26]. Nevertheless, clinical developments require 
considerable financial support from investors and, as demonstrated recently, the investors’ 
enthusiasm for funding biotechnological companies is more focused on later-stage projects 
with demonstrated performance, which require extensive clinical trials and detailed long-term 
studies. Therefore, this technology will need to be developed in partnership with big 
pharmaceutical companies to be available in developed countries. Furthermore, clinical 
studies may undergo failure or delays and the unexpected long-term side effects associated 
with pSi are yet to be assessed in clinical practice. Another factor to consider is the increasing 
competition from established treatments and other nanomedicines with faster development. 
Despite these challenges, pSi offers a set of promising opportunities based on its unique 
properties.  
This review presents the most recent advances in pSi-based drug delivery systems 
with an overview on the fabrication, properties and applicability of this nanomaterial for drug 
delivery and theranostic applications (Figure 1). We focus our attention on drug delivery 
concepts and systems with a critical overview of the advantages and intrinsic limitations of 
this technology. We provide detailed information on recent progress in the clinical translation 
of pSi-based systems for different therapies and medical treatments. Finally, we conclude this 
review with an outlook on the future challenges and trends in this exciting and dynamic 
research field. 
2. Fabrication and Properties of Porous Silicon  
2.1. Fabrication 
pSi structures are produced by electrochemical etching of silicon wafers in hydrofluoric acid 
electrolytes based on organic solvents such as acetonitrile (CH3CN), dimethylformamide 
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(C3H7NO) and ethanol (C2H6O) [13-15]. In this electrochemical process, the silicon wafer 
acts as anode with platinum wire typically used as cathode, the application of a current bias 
between anode and cathode results in the selective dissolution of the crystalline structure of 
silicon into a porous form. The structure of pSi, reported for the first time by Watanabe and 
Sakai in 1971, can be precisely engineered by the fabrication conditions (e.g. anodization 
current, type of silicon wafer, level of doping, illumination, patterning, electrolyte and 
temperature) [27]. Table 1 summarizes the most representative conditions and pore 
morphologies for pSi structures produced by electrochemical etching. 
2.2. Physical Properties 
pSi structures can be produced with a plethora of pore morphologies, sizes and geometries 
which can be engineered by electrochemical etching conditions and the pre- and post-
treatments of the pSi, such as photolithography, wet chemical etching in alkaline etchants, 
thermal treatments, etc. pSi structures can be classified into three categories according to 
their pore size (dp): namely; i) micro-pSi (μpSi – dp < 2 nm), meso-pSi (mpSi – 2 nm < dp < 
50 nm) and macro-pSi (MpSi – dp > 50 nm).  
3. Biocompatibility of Porous Silicon 
When considering the use of pSi for medical applications the highest importance is placed on 
the safety and wellbeing of patients administered any pSi-based treatment. Hence, much work 
has been directed towards assessing and demonstrating the biocompatibility of pSi-based 
biomaterials. The biodegradation of pSi [18] is dependent on several factors including the 
acidity of the local environment and intrinsic properties such as size, porosity and chemical 
functionality [30-35]. However it has been demonstrated that pSi and its degradation products 
are non-cytotoxic both in-vitro and in-vivo [28,29]. In 1995 the first investigation of pSi 
biocompatibility showed the successful growth of hydroxyapatite on pSi substrates [18]. 
Soon after, Popplewell et al. [36] determined that orthosilicic acid, a product of pSi 
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degradation in the body, is readily absorbed, gastrointestinally and subsequently excreted via 
the urinary system. Additional research has shown that orthosilicic acid is linked to 
homeostasis and regulation of key processes in the body like bone mineralization, collagen 
synthesis, skin, hair and nails health atherosclerosis and immune system enhancement [36, 
37]. These two factors demonstrated the potential biocompatibility of pSi and enable this 
material to be used for biomedical applications.  
The performance of pSi as a biomaterial is dependent on being able to control and stabilize its 
surface chemistry [38]. Freshly prepared electrochemically etched pSi surfaces are hydride-
terminated (Si-H) [39]. After fabrication and upon exposure to air and aqueous media the Si-
H terminated surface is highly unstable and rapidly converts to a mixed oxide surface [39]. 
To promote a controlled surface chemistry with less variability, pSi surfaces can be 
intentionally oxidized with ozonolysis or thermal oxidation to result in stable Si-OH or Si-O-
Si groups on the surface [39, 40]. Si-OH functionalized pSi surfaces are stable, hydrophilic 
and compatible with further silane chemistry. Thermal oxide layers (Si-O-Si) are more bio-
inert than Si-OH surfaces whilst pSi surfaces can be passivated by thermal nitridization [41, 
42], thermal carbonization (TC) or thermal hydrocarbonization (THC) [43, 44]. The benefits 
of the more intensive TC processing of pSi include improved electrical and thermal 
conductivity, combined with greater mechanical strength and robust nature of the Si-C 
surface functionality [45].  
Once stabilized the pSi surface can be modified with different chemical functionalizations via 
techniques such as silanization and more recently hydrosilanization [46]. Si-OH terminated 
pSi can be further modified with chloro or alkoxysilanes in ambient or elevated temperature 
conditions [47]. This allows for the introduction of functional groups such as amines, 
isocyanates, methacrylates and PEG moieties as well as other functionalities available by 
conventional organic synthesis routes [48]. The chemistries introduced by silanization can 
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then be used for further modification via commercial or custom made cross-linking agents, 
some even allow for the direct conjugation to various biomolecules, to promote cell adhesion, 
protein absorption or even anti-fouling surfaces [48]. The readily formed Si-O-Si bonds 
undergo hydrolysis, making the surface moderately unstable in aqueous solutions [49]. More 
stable pSi surfaces can be fabricated via the derivatization of Si-H terminated pSi directly, via 
the hydrosilylation reaction. This reaction forms more stable Si-C bonds on the pSi surface, 
by exposing the Si-H surface to alkene, alkyne or aldehyde groups [37]. This hydrosilylation 
reaction can be promoted by numerous methods including thermal, chemical, photochemical, 
electrochemical and microwave methods [50].  
Subsequent pSi functionalization can also be performed via click chemistry [51] methods or 
with various polymers via polymer grafting techniques. These techniques include “grafting 
from”, “grafting to” and “grafting-through” methods [52]. Modification of pSi with polymers 
can help to reduce brittleness, improve stability and also provides additional features such as 
pH [53], temperature [54] and ligand responsiveness [52]. Polymer modified pSi materials 
also display improved degradation control and drug release kinetics [52].  
3.1. In-vitro, Ex-vivo and In-vivo Studies using Porous Silicon 
3.1.1. In-vitro Studies using pSi 
pSi has been extensively studied in-vitro since Bayliss et al. in 1999 [55]. The authors of this 
paper investigated the biocompatibility of two cell lines (Chinese hamster ovary and rat 
neuronal B50 cells) and in a follow up paper the authors demonstrated that cell growth was 
preferred on pSi in comparison to glass [56] (Figures 2a and b). Since the late 1990's pSi has 
been used widely for in-vitro experiments with various cellular responses differing based on 
the particle size and chemistry of the pSi surface [57-59].  Table 2 summarizes several in-
vitro studies evaluating pSi and cell interactions. Recent in-vitro studies of various pSi 
formulations have found effects such as: concentration dependent cytotoxicity [60], particle 
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size and concentration dependent apoptosis and cell damage [61], enhanced cell proliferation 
and attachment [62], the ability to produce and suppress ROS formation [63] and the 
enhanced association of pSi and drug permeation to and across cell membranes [64, 65]. All 
these effects are caused by variations in the size, shape or surface chemistry of the pSi; 
highlighting the need for robust in-vitro assessment of the material before moving to further 
in-vivo and clinical studies. 
3.1.2 Ex-vivo Studies using pSi 
pSi can be intrinsically luminescent [66], conjugated with dyes [67] or other contrast agents 
[67-70] and these features can be exploited to image target tissues or organs either in whole 
animals or after resection from the animal [71]. However, most ex-vivo applications of pSi 
have been studied for tissue engineering [72] or sensing of biomolecules [66]. The ability of 
pSi to act as a support for cell growth [73] lends itself towards the ex-vivo regeneration of 
tissues and eventually organs [74] with the potential to be used to grow a patient’s own skin 
for later autografting or a donor’s cells for allografting onto burns or other serious wounds. 
Ex-vivo applications with pSi can benefit from manipulating the excellent optical properties 
of the underlying pSi for reporting the health of the cells [75] and for the reporting of the 
delivery of drugs from within the pSi scaffold [76]. Various biomolecules and even their 
metabolites can be detected using ultra-sensitive mass spectroscopy techniques [48].  
3.1.3. In-vivo Studies of pSi 
Studying the performance of pSi in-vitro and ex-vivo is completely different to in-vivo 
applications due to the complex, dynamic and responsive nature of a living animal model. 
The natural immune system that all animals possess is readily active to combat foreign 
objects. Immune responses typically elicited to the presence of foreign bodies, such as pSi, 
include enzyme degradation, the mononuclear phagocyte system (MPS), cell membranes, 
interstitial pressure and efflux pumps [77, 78]. Implantation of pSi in-vivo for extended 
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periods can result in inflammation around the implant and may also cause the formation of 
fibrotic capsules, meanwhile, the by-products of modified pSi degradation may also cause 
cascades of unpredicatable events. Hence, in-vitro and ex-vivo results of pSi experimentation 
cannot be relied upon for conclusive performance evaluation of pSi in in-vivo systems. 
Furthermore, in-vitro and ex-vivo systems cannot ascertain crucial factors for example 
biocompatibility, biodistribution, resorption rate, or chronic/acute toxicity [77]. Low et al. 
[79] examined the potential of pSi membranes as implantable scaffolds by first oxidizing and 
aminosilanizing the pSi prior to implantation in the conjunctiva of rats (Figure 2c). Over 8 
weeks the implants showed a slow degradation rate and a thin fibrous capsule with very little 
evidence of inflammation at the implant interface. There was no tissue erosion or 
neovascularization observed. This study demonstrated the use and potential of pSi as an 
implantable scaffold. Table 2 summarizes pSi-based materials in-vivo. 
3.2. In-vivo Administration of pSi 
Each pSi administration route; intravenous, subcutaneous, oral or other, will vary in 
efficiency and bioavailability. Hence, dramatically different biological responses could be 
observed when pSi is implanted/administered to different tissue, even for the exact same 
material [80].  
3.2.1. Intravenous Injection 
Intravenous injection (IV) allows for the systemic administration of pSiNPs, lending itself 
towards targeted applications. However, IV requires the specific functionalization of the pSi 
surface with the correct targeting ligands to direct the pSi and the payload it is carrying to the 
desired organ or site of pathology [74, 81]. Once adequately functionalized with targeting 
molecules, pSi can adequately hone to specific sites such as the stroma of panceratic tumor 
mouse functionalized with the Ly6C antibody [82]. pSi and other materials administered 
intravenously are likely to suffer from opsonization, which occurs when the MPS entraps the 
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material [83]. Here, once again, the surface chemistry/properties and size of the particles play 
an important role in avoiding or promoting opsonization, clearance and or cellular uptake 
[84]. Other properties that have a significant effect on biodistribution include particle size, 
shape, surface charge and morphology. Typically, particles larger than 200 nm activate the 
complement system more efficiently and are therefore cleared faster than sub 200 nm 
particles.  
3.2.2. Subcutaneous Injection 
Particles injected subcutaneously (SC) are trafficked in a size-dependent fashion to the 
lymphatic system [85]. This size dependence occurs due to large particles being consumed by 
peripheral antigen presenting cells (APCs) and smaller particles being internalized by 
resident APCs after cell-free trafficking [85, 86]. Hudson et al. [87] demonstrated little 
toxicity of mesoporous silicates following subcutaneous injection in rats. However, 
intraperitoneal and intravenous injections caused either death or the animals needed to be 
euthanized. They reported the cause of the death was due to the formation of thrombus [87]. 
An in-vitro cytotoxicity study, determined that smaller particles were reportedly the most 
toxic, whilst surface chemistry also played a key role in determining toxicity [47]. 
Subcutaneous pSi delivery systems are a particularly attractive option for the delivery of 
newly developed peptide drugs, which possess relatively short half-lives [88]. Various pSi 
functionalizations (thermally oxidized pSi, undecylenic acid-modified thermally 
hydrocarbonized pSi and thermally hydrocarbonized pSi) have been investigated for 
sustained subcutaneous peptide delivery [88]. The continued study into the in-vivo 
cytotoxicity and biocompatibility of silicon structures are essential for ensuring their use in 
future biotechnological applications [89].  
3.2.3. Oral Administration 
Oral administration is the most common route of administration for pSi drug delivery 
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applications as it is convenient, safe and inexpensive. The biggest drawback with oral 
administration, however, is the presence of digestive enzymes and the low pH in the stomach. 
These two factors in combination with the mostly low permeability of the intestinal walls can 
lead to further delivery difficulties. Fortuitously, pSi particles possess more stability at acidic 
pH’s than alkali; hence, pSi is somewhat resistant to the gastric fluids of the stomach. 
Furthermore, pSi provides a small pore size to confine the drug in a completely tunable 
fashion [21, 90, 91] and coating pSi with enteric polymers permits tunable release at the 
desired pH [42].  
3.2.4. Comparison of Biodistribution Following Various Administration Routes 
Bimbo et al. demonstrated that pSiNPs distribute via different pathways after different 
administration routes [92]. Radiolabelling pSiNPs allowed them to observe that the pSi 
accumulated in the spleen and liver after IV delivery, but mostly in bone and the 
gastrointestinal tract when administered by SC and oral route, respectively. There are further 
studies, in small animal models, demonstrating that intraperitoneal injections result in 
absorption into circulation via peritoneum and are proposed to be as efficient as IV for 
general drugs [93] and even NPs [94]. Much more work is required to further our 
understanding of the complex biological reactions elicited by the immune system, when these 
porous nanomaterials are administered in-vivo via various routes, before we can safely move 
to regular and routine clinical trials. 
3.2.5. Clinical Trials 
Two products from pSivida Corp., MA, USA have been approved by the FDA; Iluvien® and 
Retisert®. Both are used for the treatment of ophthalmic conditions like Diabetic Macular 
Edema and Uveitis and are marketed by Alimera and Bausch and Lomb, respectively [95]. 
These two products are based on the DurasertTM technology, which is an injectable, non-
erodible, intravitreal implant, developed by pSivida, these systems are primarily polymer 
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based sustained delivery solution. pSivida are currently developing the DurasertTM 
technology to deliver Latanoprost, this technology is licensed to Pfizer Inc. for the 
development stage and currently under Phase I/II clinical trials. Currently, pSivida is 
developing a controlled release ophthalmic delivery system based on nanostructured silicon, 
Tethadur, to provide the long-term sustained release of biologics to the eye. Additionally,  
other clinical trials have occurred for the non-commercialized BrachySilTM, pSi with 32P 
radioactive isotope incorporated used for brachytherapy, from pSiMedica (a subdivision of 
pSivida) [96, 97]. BrachySilTM is injected into the tumor under a local anesthesia and delivers 
radiation (β-emission) through around 8 mm of tissue [98]. During the trial the toxicity was 
assessed by the nature, incidence and severity of adverse events and by hematology and 
clinical chemistry parameters. The preliminary data for the initial safety study presented at 
American Society of Clinical Oncology (January 2008), claimed improved disease control in 
82 % of patients treated with BrachySilTM.  
3.3. Drawbacks and Limitations, Approaches to Overcome Inherent Disadvantages, 
Advantages, Recent Advances and Future Trends 
In-vitro studies are an ideal tool to gain an overall understanding of the biocompatibility or 
cytotoxicity of a biomaterial [69, 99]. Typical important cell behaviors assessed include 
viability, proliferation and phenotypic change [100-102]. However, in-vitro tests do not 
effectively represent complex in-vivo environments. More controlled in-vitro assessments 
enable faster reproducible testing platforms for biomaterials [69]. Consequently, it is very 
important to perform in-vitro studies prior to in-vivo test and any clinical assessments. 
Conventional in-vitro, cell viability assays examining biomaterials can highlight the release 
of toxic agents in specific biological fluids and indicate if a material is suitable for a specific 
physical location [100]. The most severe cellular effects are often observed if a biomaterial is 
releasing toxic agents that produce apoptosis and necrosis [65, 100, 102]. Compatibility 
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issues can arise when pSi is placed into conventional cell-based assays. Once again, the 
adequate control of the pSi surface is crucial to inhibit the generation of ROS and avoid these 
unwanted interferences [49]. Thus far extracellular ROS generation by pSi appears to be 
dependent on the protein concentration in the assay environment [103], indicating that the 
effect will vary both in-vitro and in-vivo. Despite the recent developments in pSi-based drug 
delivery systems and advantages like tunable pore size, particle size and surface chemistry, 
high loading capacity, ability to protect sensitive payloads, intrinsic photoluminescence (PL), 
biocompatibility and biodegradability and many others, the key limitations remain 
unresolved. The challenges in the field of pSi particles based nanomedicine include fast 
dissolution under physiological condition, redox activity, low PL quantum yield, poorly 
understood in-vivo characteristics, etc., all of which need to be overcome before 
commercialization of pSi nanoparticles based therapeutic systems. 
In summary, pSi particle accumulation and bioavailability will depend on the administration 
route and particle size, there are now many studies demonstrating the susceptibilities of 
various cell types [104-106]. Future in-vivo studies with various pSi particle preparations 
need to be watchful of the toxicity and preferential accumulation in different organs of the 
host.  
4. Porous Silicon for Drug Delivery Applications 
4.1. Porous Silicon as a Platform for Drug Delivery Applications 
The key properties that make pSi attractive for drug delivery applications are its highly 
controllable pore size, morphology, surface chemistry, biocompatibility and biodegradability. 
The pores of pSi can host large quantities of drug molecules and even concentrate them to up 
to 400 times compared to the same volume of pure therapeutic solution due to ultra-high 
surface area and huge pore volume [107]. This was demonstrated by loading bevacizumab 
(avastin) into pSi and the concentration factor was defined as the ratio of the mass of the 
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avastin in the pSi film per unit volume to the mass of drug in the initial loading solution per 
unit volume.  In addition, loading of a drug inside pSi pores prevents crystallization providing 
a better control over drug availability and dissolution profile [21, 108]. pSi particles are able 
to protect sensitive proteins from degradation and enzymatic denaturation in the stomach 
[109]. Furthermore, the photonic properties of pSi substrates, imparted during the 
electrochemical fabrication process, have been demonstrated for reporting the release of the 
therapeutic payload [107]. 
4.2. Porous Silicon Films for Implantable Drug Delivery Solutions  
pSi-based photonic crystals can be generated simply by varying the current-time profile 
during the electrochemical etching process [14] and demonstrate a linear correlation between 
the optical response and concentration of the released payload (dexamethasone) [110]. A 
similar optical structure was also used to load and release avastin, an antibody used for cancer 
treatment and certain ophthalmic diseases [107]. The ease of fabrication and modulation of 
pore morphology of pSi was utilized by Vaccari et al. to fabricate a bi-layered structure with 
a macroprous layer (2 µm) covered by a nanoporous layer (200 nm) [111]. This bi-layered 
porous structure was loaded with doxorubicin (DOX), an anticancer drug, by immersion 
loading. A biphasic release profile was obtained with a burst of DOX released for 5 h 
followed by a slower release. This structure was also tested in an in-vitro cell study using 
human colon adenocarcinoma cells (LoVo and HT29) with no significant anti-proliferative. 
Perelman et al. demonstrated a pH triggered system based on pSi thin films for the release of 
vancomycin [112]. The pSi carriers were loaded with vancomycin using immersion loading 
followed by pore capping by serum albumin protein (BSA) at pH < 4. The pH trigger 
mechanism is based on the pSi isoelectric point 4 with adsorption of BSA at pH < 4 and 
desorption at pH > 4. 
4.3. Porous Silicon Microparticles for Local, Oral and Ophthalmic Delivery Solutions 
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pSi films can be detached from the underlying bulk silicon by simply setting the etching 
conditions to the electropolishing regime. The key advantage of the lifted-off pSi membrane 
is that it preserves the structural and morphological features of a pSi chip with the ability to 
be broken into smaller fragments of macro- or micro-dimensions by sonication [14]. pSi 
microparticles (pSiMPs) are limited to local, oral, or ophthalmic delivery solutions due to 
size constraints. pSiMPs have used to deliver payloads like poorly soluble hydrophobic small 
molecules drugs (e.g. furosemide, ethionamide, ibuprofen, griseofulvin, indomethacin) [113-
115] and proteins (e.g. insulin, serum opsonins, bovine serum albumin, glucagon-like 
peptide-1) [116-118]. Besides, the loading and release of therapeutic payloads pSiMPs have 
also been tested for their bioactivity and compatibility [62]. Another study by Wu et al. 
reported the degradation of redox activity drugs inside pSi can be prevented by either surface 
modification, thermal oxidation, or thermal carbonization [119]. Salonen et al. systematically 
compared the loading and release of five different small molecules (three poorly soluble 
drugs; ibuprofen, griseofulvin and furosemide and two water soluble drugs; ranitidine and 
antipyrin) of varying hydrophobicity from thermally oxidized and carbonized pSiMPs [113]. 
The loading varied between 9 % and 45 % for thermally carbonized pSiMPs, while the 
release rate was found to be dependent on the dissolution behavior of the loaded drug with 
the pSiMPs delaying the drug release. Bullpit et al. reported significantly improved 
bioavailability of immunosuppressant drug cyclosporine A after loading into the pSiMPs 
[20]. After a single subcutaneous injection of cyclosporine A loaded into pSiMPs, the blood 
concentration of cyclosporine A in CD rats was increased by approximately 280 % compared 
to the control group, in which equal mass of cyclosporine A was injected in simple phosphate 
buffered saline. The pores of pSi act as containers that can house a sensitive payload and 
protect it from harsh environments, which is why it has been employed for delivery of 
proteins and peptides through oral delivery. Delivery of insulin is most widely studied from 
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pSiMPs, where pSi has been shown to enhance the bioavailability of insulin while protecting 
it against the low pH and digestive environment of the stomach [120]. Sreshtha et al. loaded 
insulin into chitosan modified thermally hydrocarbonized pSiMPs and tested for permeation 
across a CaCo2/HT-29 cell monolayer [121]. They observed a 20-fold increase in the amount 
of insulin permeated and 7-fold increase in the apparent permeability (Papp) value in 
comparison to the pure insulin across the CaCo2/HT-29 cell monolayer. In a recent study, the 
same group used thiolated and cell penetrating peptide modified pSi particles for oral 
delivery of insulin (Figure 3a and b) [109]. Similar results were reported by Pastor et al. 
using chitosan coated pSiMPs [120]. Besides insulin, other proteins like Cry5b (an 
anthelmintic protein), which was shown to be active in eradicating stomach worm, C. 
elegans, effectively even after incubating the Cry5b loaded pSiMPs in simulated gastric fluid 
(SGF). (Figure 3c).  
pSiMPs have been extensively exploited for intravitreal delivery [122-124]. A key study 
reported intravitreal distribution and clearance after ocular injection of pSi and oxidized 
pSiMPs [125]. The results revealed that both pSi and oxidized pSi are non-toxic in rabbit 
retina and degrade into silicic acid over time. Hou et al. loaded Daunorubicin (DNR) for 
intravitreal delivery for inhibition of VEGF and PDGF that are responsible for 
neovascularization [124]. The study showed that oxidized pSiMPs delivery system can 
extend DNR vitreous residence from a few days to three months. In another study, the same 
group compared the DNR release from oxidized pSiMPs loaded by physical adsorption and 
covalent attachment. Covalent attachment method not only provided better loading (> 67 
µg/mg) in comparison to physical adsorption (~ 27 µg/mg) but also showed better dissolution 
profile in-vivo with DNR still detected after more than three months in rabbit eyes (Figure 
3d and e). Wang et al. used similar pSiMPs for intravitreal delivery of dexamethasone 
(DEX), a glucocorticoid [126]. They showed that in-vitro DEX release lasts up to 90 days in 
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comparison to only 10 days for free DEX. The in-vivo study showed no sign of ocular 
toxicity in rabbit eyes (at 3 mg) after intravitreal injection and drug level of 107.23 ± 10.54 
ng/mL (at 2-week mark), which is well-above the therapeutic level. The most interesting 
development for the use of pSiMPs for intravitreal delivery of therapeutics include their self-
reporting ability based on the changes in the photonic properties over time due to 
degradation, which can be correlated to the drug release [123, 127]. In a pioneering study, the 
Sailor group demonstrated that it is feasible to visualize the pSiMPs and their photonic 
signature in-vivo in rabbit eye, which was used to assess the degradation state of the particles. 
An extension of this study focused on rugate pSi particles loaded with two model drugs, 
rapamycin and DEX, loaded by physical adsorption and covalent attachment, respectively. 
These drugs were tested to monitor the feasibility of drug release from the pSi particles 
through a color fundus camera imaging [123]. pSi particles with adsorption loaded rapamycin 
displayed violet color, which was negatively correlated to the rapamycin released into the 
vitreous. DEX was covalently loaded onto the fully oxidized pSi rugate particles that 
appeared yellow in vitreous and decreased over time with a strong correlation with the DEX 
detected from the vitreous samples. 
4.4. Advantages and Disadvantages of Porous Silicon Drug Delivery Platforms 
The countable advantages of pSi for drug delivery include: (i) confinement of the drug 
molecules into the pores to prevent crystallization; (ii) protection of the sensitive payloads 
from harsh conditions; (iii) release kinetics can essentially be tailored to suit the requirements 
by tuning the pore morphology; (iv) high drug loading (up to 60 % by mass) and 
concentration (up to 400 times); (v) surface chemistry tunability to control the drug loading, 
release, dissolution and biocompatibility; (vi) surface chemistry to attach targeting moieties 
to pSi particles to deliver the payloads specifically to diseased organs; (vii) the 
electrochemical etching systems are commercially available with variable degree of 
19 
 
automation (AMMT systems, Germany) and is utilized by companies like TruTags inc. and 
Spinaker Biosciences. It is worth noting that pSiNPs have shown great potential for systemic 
drug delivery, but localized and implantable drug delivery systems based on pSi are 
inherently limited by the intrinsic instability of pSi under physiological conditions. For oral 
delivery systems based on pSi, most studies have only investigated the release and dissolution 
characteristics under in-vitro conditions. Therefore, it is essential to further carry out in-vivo 
investigations to fully understand the release characteristics and dissolution of the pSi carrier. 
A recent example of important differences between in-vitro and in-vivo release 
characteristics of pSi substrates was reported by Wu et al., who demonstrated that pSi can 
load and deliver the protein payload (Cry5B) to eliminate stomach worms under in-vivo 
conditions [128]. However, during in-vivo testing it was observed that pSi particles were 
cleared out in the faeces before they dissolved and released their payload. Therefore, novel 
methods are required to specifically tune the release profiles of different payloads under 
different conditions to obtain better in-vitro to in-vivo correlation. The limitations of pSi for 
local and implantable systems might be overcome by utilizing oxidized pSi, whereas oral 
delivery of therapeutic will require better designing of pore morphology, structure and 
surface chemistry. For self-reporting ophthalmic delivery, the key issue has been angular 
dependence of the photonic properties of pSi particles and the roughness of the surface 
resulting in increased scattering. One of the key future directions for pSi-based therapeutic 
agents would be as multivalent pSi systems, which not only deliver therapeutics with desired 
kinetics but also help in imaging based on inherent long-lived photoluminescence that can be 
used for both continuous-wave and time gated photoluminescence based imaging. 
5. Porous Silicon for Sensing and Theranostics 
5.1. Introduction 
pSi can be used to detect biomedically relevant species from small molecules such as 
20 
 
metabolites, to large molecules such as DNA, proteins and even whole organisms such as 
viruses and bacteria. There are some extensive reviews discussing sensing with pSi available 
in the literature [129,130]. The most attractive properties of pSi for biosensing applications 
are its high surface area [131], made-to-measure pore structure [132,133] and exceptional 
optical characteristics. 
5.2. Types of sensing systems based on porous silicon 
Optical biosensing with pSi is the most common format of pSi biosensors [134]. These 
optical pSi sensors originally consisted of thin films [135], but have advanced to structures 
such as microcavities [136,137], rugate filters [110,138], Bragg mirrors [139] and 
superlattices [140,141]. These sensors use small but monitorable changes in the optical 
reflectivity of pSi to enable detection of virtually any biological analyte including: proteins, 
enzymatic activity, DNA, viruses and even whole bacteria [129,130,132]. pSi-based sensors 
have also been used in the detection of hazardous organic molecules and explosives 
[142,143].  
White light interferometry is commonly used to sense the changes in optical properties upon 
the binding/infiltration of an analyte into the pSi pore structure. The infiltration of various 
molecules into the pSi layer causes a change in the refractive index allowing for label-free 
detection [135]. These highly sensitive shifts can be exploited to sense down to the sub-
picomolar range and are generally considered more sensitive when blue-shifting rather than 
red-shifting [130]. However, these biosensors can suffer from Effective Optical Thickness 
(EOT) drift and interferences can occur when analysing complex matrices, such as bodily 
fluid [130]. The minimization of these effects has been overcome by the development of 
pSi-based sensors with multiple layers, that can act to separate/exclude biomolecules of 
certain sizes [144]. The further development of Bragg reflectors, microcavities and 
sinusoidally etched rugate filters have allowed for the tailored improvement of biomolecule 
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sensing [130] as well as enabling applications such as smart-Petri dishes for live cell 
monitoring [76] and analyte sensing in whole blood [145]. Whilst superlattices, or spectral 
barcodes, have enabled discrimination between analytes such as rat and bovine serum 
albumin [110]. Photoluminescent (PL) based biosensing is also possible since pSi shows 
intrinsic PL at room temperature [16]. However, this method is not used as regularly as white 
light interferometric techniques, due to the greater error in measuring PL changes compared 
to wavelength shifts and the vulnerability of PL surfaces to quenching by a wide range of 
species [130]. However, recent work has focussed on the enhancement of luminescence using 
pSi microcavities and achieving limits of detection in the order of 150 nM [146].  
5.3. Surface Chemistry Modification of Porous Silicon for Selective Sensing of 
Biomolecules 
To design a selective sensor, pSi must be successfully covered with the correct sensing 
molecule. There exist many different methods for covalently attaching molecules such as 
peptides [147], proteins [148], enzymes [149], antibodies [81] and DNA [150] to pSi. 
Generally, moieties linked to the pSi surfaces react with either amine or thiol groups 
contained in the biomolecule being targeted. These species typically include isocyanates [47], 
epoxides [151] and N-hydroxysuccinimide [72] among many others [152]. When considering 
immobilizing biomolecules one must consider not only the surface coverage and stabilization 
but also the retention of the biological activity of the linked species [153]. Recent advances 
have also allowed for the dual functionalization of pSi with two different chemistries both 
laterally [47, 72] and vertically [154, 155]. To pattern laterally uses photolithographic 
techniques and has been used for both silanization [47] and hydrosilylation [72]. Vertical dual 
functionalization is performed by exploiting the wettability of the pSi when functionalizing 
[154, 155].  
5.4 In-vitro and In-vivo Biosensing 
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Typically, most sensing applications with pSi thus far have been performed in-vitro. This 
however is not conducive to translation into implantable devices as the current optical 
sensing method, namely white light interferometry, requires an unobstructed path to the pSi 
surface where the interactions are taking place [130]. Similarly, it is evident that pSi sensors 
that work under controlled conditions often begin to fail when challenged with the milieu of 
components in biological samples [130]. In-vitro sensing with pSi is beneficial for 
applications where sampling is relatively straight forward, for example glucose biosensors for 
diabetic chronic wound healing [156], however, optical sensors fall well short when required 
in-vivo for very low concentration biomolecules such as Troponin, which only spikes in the 
heart muscles shortly before cardiac arrest [157]. The need to develop pSi-based sensors into 
implantable and easily interrogatable devices seems far off at this point in time. However, 
with the development of technologies such as wireless telemetry [158,159] it does seem 
likely in the future that this transition will occur. 
5.5. Theranostics Based on Porous Silicon Platforms 
Theranostics is the combination of both diagnostics and therapy in one. The plethora of pSi 
formats (i.e. films, membranes, micro- and nanoparticles) as well as physical modifications 
(i.e. pore size, particle size, thickness and optical properties) and chemical/secondary 
modification available, opens the potential of pSi in theranostics [153]. Further investigations 
into factors such as residence time, specific disease targeting and on demand payload delivery 
are still required to optimise pSi for theranostic applications. Studies with pSi using a 
combination of diagnosis (or targeting) and treatment include works by Secret et al. [81] and 
Chiappini et al. (Figures 4a and b) [160]. These studies investigated the use of multistage 
delivery vehicles fabricated with coronas of targeting molecules around the pSi particles. The 
ability to combine modified pSi with secondary NPs allows targeting or activation via 
external stimuli. Consequently, combinations using magnetic and luminescent pSi [161], 
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Quantum Dots (QDs) in pSiMPs [162], photoluminescent pSiNPs [71] and radiolabelled pSi 
[92] are now beginning to appear in the literature. Some theranostic pSi systems exploit the 
photoluminescent properties of pSi and are photosensitizers, capable of generating singlet 
oxygen [162]. Other systems combine pSiNPs, bacteriophage and super paramagnetic iron 
oxide nanoparticles (SPIONs) into the one device allowing for the delivery of the particles 
with a therapeutic and an imaging payload to tumors [163]. These types of theranostic 
particulate systems are capable of targeting diseased tissue both in-vitro and in-vivo. These 
systems could potentially be used for a myriad of applications including cardiovascular 
disease and cancer therapy. Additionally, these pSi-based materials do not require surgical 
resection after implantation or injection due to the biodegradation of the pSi scaffold into 
silicic acid. 
5.6. Drawbacks and Limitations of Porous Silicon in Theranostics 
There are a multitude of barriers present in biological systems, which can potentially interfere 
with the theranostics applications of pSi in the body. These include: enzymatic degradation, 
phagocytosis by the reticulo-endothelial system (RES), vascular endothelia, interstitial 
pressure, cellular/nuclear/endosomal membranes and molecular efflux pumps [164]. All these 
systems can prevent particulate drug carrier systems from reaching their target site of action 
at therapeutic levels [165]. Hence, to deliver more of the payload to the required site it is 
important to control the size, shape, density and surface chemistry of the particles, properties 
which, help regulate the effects such as cell adhesion, cell uptake and flow in the bloodstream 
[166]. To overcome some of these limitations pSiNPs systems can be specifically designed 
with various geometries [82] or surface chemistries/modifications [167]. There are three 
generations of NP formulations:  
The first are passive particulate systems, which reach their intended site by exploiting passive 
mechanisms like the Enhanced Permeation and Retention effect (EPR). These first-generation 
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NPs can be coated with molecules such as PEG to avoid RES uptake [167], or opsinization 
[168] whilst also enhancing their circulation time [169]. Second generation particulate 
systems incorporate additional functionality that allow for the targeting of individual disease 
sites through the binding of specific ligands to unique markers at the site of pathology [81] or 
secondary functionalities that allow the delivery of various therapeutic agents, imaging or 
triggered/controlled release [153, 163]. Third generation systems are comprised of multiple 
components, which are designed to completely avoid the above-mentioned biological 
barriers. These functions are often timed so that the payload is released at the ideal time-point 
and in the ideal location [163]. This release can be triggered by either an internal stimuli or 
external stimuli such as heat, RF, or light [153].  
In summary, pSi properties and functionality are open to modification and able to be 
completely tailored with a diverse range of pSi-polymer or pSi-biomolecule hybrid 
architectures. This allows for the generation of a wide range of materials with well-defined 
optical and mechanical properties, as well as degradation and drug release profiles. The 
ability to perform dual operations, such as, imaging and drug delivery simultaneously, will 
lead to more advanced theranostic applications in the future. Potentially allowing for the 
specific delivery of controlled amounts of drugs on demand in response to an appropriate 
external or more beneficially a natural biological signal. In the future, smart active 
biomaterials will emerge and be commercialized that are able to perform functions such as 
targeting specific disease states, respond to in vivo stimuli in that disease environment and 
finally perform an appropriate action, such as delivering its drug payload or sequestering 
toxins. 
6. Conclusions and Future Perspectives 
pSi is a promising platform for the development of a broad variety of nanomedicines and 
drug delivery systems, which could address some of the limitations of conventional therapies 
25 
 
and existing medical treatments. pSi structures can be produced by well-established 
fabrication process developed during the last decades and a multitude of pSi-based structures 
can be fabricated with high precision and tuned chemical and physical properties. 
Furthermore, although the long-term toxicity of pSi in clinical practice is yet to be 
established, the significant amount of in-vitro and in-vivo studies on pSi structures are 
displaying promising evidence of the biocompatibility of this material. pSi structures have a 
unique set of physical and chemical properties, including high porosity, controllable 
dimensions, tuneable surface chemistry, high loading capacity, biodegradability, 
biocompatibility and biointegration. These properties make it possible to develop advanced 
and highly versatile drug nanocarriers and delivery systems, where the release of therapeutics 
can be engineered with precision per the demands of specific medical treatments. As a result 
of its optoelectronic properties, pSi structures are excellent candidates for theranostics and 
photodynamic therapies, which is an advantage over existing systems based on the 
combination of imaging and therapeutic agents.  
Although these studies have demonstrated promising and outstanding advances in pSi 
technology for drug delivery and medical applications and some companies have started to 
explore the commercialization of pSi systems, it is worthwhile stressing that this technology 
still faces both technical and commercial challenges for its ultimate clinical translation from 
bench to bedside. Therefore, more extensive fundamental research assessing the toxicity and 
side effects associated with pSi systems and their performance in terms of clinical efficiency 
will be needed before this technology becomes feasible and reliable. However, based on the 
evidences shown in the studies reviewed here, it is reasonable to conclude that there is 
considerable potential for pSi to become an alternative nanomedicine platform for therapies.      
 
7. Expert Opinion 
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pSi technology brings new opportunities with realistic potential to be translated into clinical 
therapies because of its unique properties (e.g. high porosity, high loading capacity, 
controlled releasing performance, biodegradability, biocompatibility, biointegration and self-
reporting and imaging features). These factors make pSi a promising candidate for a new 
generation of nanomedicines. Despite these fundamental and applied advances, it is 
worthwhile noting that pSi technology still faces important technical and commercial 
challenges. Although an extensive research activity in the last decade has aimed at 
demonstrating the in-vivo and in-vitro performance of pSi systems for different applications 
and therapies (e.g. oncology, theranostics, imaging, orthopedics, tissue engineering, etc.), the 
side effects, long-term toxicity and performance of this technology are yet to be demonstrated 
throughout exhaustive clinical trials. From a commercial point of view, it must be pointed 
that drug delivery technologies achieve the highest value after commercialization or when 
they are close to regulatory approval. pSi technology is still in its early-mid phase of clinical 
development, which is not the optimal stage for valuation and capturing the investors’ 
interest. Clinical trials can experience delays and failure and strong financial support is 
required during this stage of development. Therefore, pSi technology will need to be aligned 
with pharmaceutical sectors to stimulate the investors’ support and to penetrate markets in 
developed countries through partnership. Furthermore, the increasing competition in the 
biotechnological sector with the presence of fast-developing nanomedicines and well-
established medical treatments are factors that could reduce the market size for pSi 
technology. Nevertheless, in contrast with other drug delivery technologies, pSi has potential 
broad applicability, making it an attractive technology for targeting a significantly wide range 
of niche markets (e.g. cancer, ocular diseases, orthopedics, tissue engineering, photodynamic 
therapies, diagnostics, etc.). pSi systems offer unique concepts and approaches that are 
distinctly different from existing competitive technologies such as liposomes and polymers. 
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These factors make pSi technology a highly promising platform for boosting the production 
of a new range of nanomedicines and advanced therapeutics. Furthermore, given its 
optoelectronic properties, pSi technology can be easily integrated into implantable and 
biodegradable electronics, which is perfectly aligned with existing bionic devices currently 





• Electrochemically and chemically engineered pSi structures are envisaged as a 
unique platform for drug delivery and theranostics because of its chemical and 
physical properties and structural versatility. 
• Fabrication of pSi by electrochemical or chemical etching of silicon provide a 
means of engineering a unique set of porous structures based on this material, 
which can find broad applicability in biomedical applications. 
• pSi structures have a set of unique optoelectronic properties as well as 
biocompatibility and tuneable biodegradability, making this material a promising 
candidate for the development of advanced biomedical devices and systems for 
drug delivery, photodynamic therapy and diagnosis. 
• The performance of pSi for different biotechnological applications has been 
demonstrated by a multitude of in-vitro and in-vivo studies aiming to explore the 
capabilities of this material for drug delivery, diagnosis and imaging, complex 
biochips systems and tissue engineering. 
• Although some companies have initiated the commercial development of 
nanomedicines based on pSi, the bench-to-bedside translation into clinical 
nanomedicines faces both technical and commercial challenges. 
• These clinical developments will require considerable financial support from 
investors and extensive clinical trials and detailed long-term studies before this 
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Table 1. Compilation of the most representative electrochemical etching conditions used to 
















































Wide long pores  
with high wall roughness 
80% 




Medium long pores  
with dendritic branches 
50% 




Narrow long pores  




















Wide long pores with  
low wall roughness 
35% 




Narrow long pores with  
dendritic branches 
45% 








Narrow long pores with  
dendritic branches 
20% 








Table 2. Summary of the most representative in-vitro, ex-vivo and in-vivo studies using porous silicon-based materials. 
Form of pSi Surface modification In-Vitro In-Vivo Cell type Animal Model Reference 
Films Fresh X - Rat neuronal (B50) - [55] 
Films Fresh X - Rat neuronal (B50) - [56] 
Film Oxidised X - Hepatocytes - [57] 
Film Undecylenic acid and poly(styrene) X - Hepatocytes - [74] 
Films Fresh, Ozone, Amine, PEG, Collagen and FBS X - Rat pheocheromocytoma (PC12) - [62] 
Film 






Films Amine, PEG X - Human neuronal (SK-N-SH) - [47]  
Film Peptide X - Rat mesenchymal stem - [148]  
Film Oxidised X - Human mesenchymal stem - [59]  
       
Membrane Oxidised, Amine X X Human lens epithelial Rat [79]  
       
MP Amine +/- PEGylation X - THP-1 monocytes - [34,35] 
MP Oxidised, Amine X - J774A.1 macrophages - [69] 
MP Amine - X - Mouse [75] 








       
NP THC X X -RAW264.7 Macrophage Rat [92] 




B lymphocytes (Raji), T-cells 
(Jurkat), monocytes (U937) 












Figure 1. Diagram showing the fabrication process for materials based on pSi structures, 
with the electrochemical etching of silicon wafers (pSi films), lift-off of the film (pSi 
membrane), sonication (pSi microparticles – pSiMPs) and further sonication (pSi 








Figure 2. (a) SEM images of hydroxyapatite crystallites on pSi surface exposed to simulated 
plasma for (top) 25 and (bottom) 30 days (adapted from [55]). (b) Cross-sectional SEM of 
B50 cells grown on pSi surfaces after 72 hours (top) and optical image of Fura 3 dye B50 
cells superimposed on the pSi substrate image (bottom) (adapted from [56]). (c) Thermally-
oxidised, aminosilanised pSi membranes implanted under the rat conjunctiva, shown 







Figure 3. (a) A schematic of the two strategies of thiolation of porous silicon used by 
Shrestha et al. for oral delivery of insulin ([109]). (b) In-vitro insulin release curve obtained 
by the particles prepared by the thiolation methods shown in (a) (adapted from [109]). (c) 
Merged fluorescence/differential interference contrast (top panels) and fluorescence (bottom 
panels) images of C. elegans incubated with rhodamine-labelled pSi nanoparticles. A: 
Untreated young adult with the relevant anatomical features indicated. B: Worm incubated 
with 0.4 μm rhodamine-labelled pSi particles for 2 h (rhodamine label can be seen throughout 
the lumen of the intestine). C and D: Higher magnification images of pharynx and anus 
regions of worms treated under the same conditions as in B (adapted from [127]). (d) Fundus 
photographs of the rabbits, monitored for 5 weeks post-injection of the pSi particle 
formulation. The particles show up as dark or predominantly violet colored features in the 
images ([123]). (e) Drug released and evolution of color classes as a function of time in-vivo 
for the pSi particles based self-reporting formulation injected into rabbit eyes at day 0 








Figure 4. (a) Immunofluorescence microscopy image of the pSiNPs targeting motor neurons 
cells growing on astrocytes (left) and flow cytometry images of DOHH-2 cells and Jurkat 
cells, incubated with pSi-Rituximab labeled with FITC (right) (adapted from [81]). (b) High-
throughput fabrication of pSiMPs by combining lithography and etching (left) and in-vivo 
images of pSiMPs conjugated with C5.5 Alexa dye (right) (adapted from [160]). 
